Highlights: Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia, the United States, and Italy Presented compelling bioMUSE data at two prestigious industry conferences Granted a 20-year patent for 100 new compounds targeting Parkinson's...